Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pegydone
- Development stage
- Preclinical
- Lead developer
- i-Cordis
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Pegydone is a PEGylated small molecule derivative of the immunomodulatory drug pirfenidone, currently under development by i-Cordis. Designed as a new molecular entity, Pegydone utilizes a small PEG chain conjugation to address the gastrointestinal tolerability issues and poor pharmacokinetics associated with the parent compound. It is primarily being investigated for its cardioprotective and anti-fibrotic effects in conditions such as heart failure with preserved ejection fraction (HFpEF), post-myocardial infarction heart failure, and muscular dystrophy-associated cardiomyopathy. Preclinical studies suggest that Pegydone offers superior therapeutic effects and reduced toxicity compared to pirfenidone, with potential applications in treating post-operative atrial fibrillation, immunotherapy-associated myocarditis, and idiopathic pulmonary fibrosis.
- Brand names
- Pegydone
- Other names
- PEGylated pirfenidone
02
Targets
TGFBR1TGFB (GARP–latent transforming growth factor beta 1 complex)TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on Pegydone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pegydone.